Home > Our Research > FXR
FXR, a nuclear receptor expressed in the liver and intestine, is a key regulator of bile acid, inflammatory, fibrotic and metabolic pathways.
In addition to their role in digestion and absorption, bile acids have been shown to bind and activate dedicated receptors like FXR.
Intercept's lead compound, obeticholic acid (OCA), is an analog of the bile acid chenodeoxycholic acid (CDCA).
You are now leaving Intercept Pharmaceuticals’ corporate website and entering a site intended for U.S. audiences only.
You are now leaving Intercept Pharmaceuticals’ corporate website. Intercept does not control or endorse the content of this external site.
The link you have selected will take you outside of Intercept Pharmaceuticals’ corporate website.
The site you will be entering is intended for U.S. audiences only.
If you are a healthcare provider looking for product information, visit ocalivahcp.com.
You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. Intercept provides this link as a service to its website visitors. Intercept is not responsible for the content or the privacy policy of any third party websites.
Close this window to return to Intercept Pharmaceuticals’ site or click ‘Continue’ to proceed.
United States (US)
European Union (EU)
Canada
Israel
Switzerland
Australia
Liechtenstein
United Arab Emirates (UAE)
Exploring Racial Differences and Disparities in PBC Care